Logo

Alnylam's Oxlumo (lumasiran) Receives the US FDA's Approval for Treatment of Primary Hyperoxaluria Type 1 in Pediatric and Adult Patients

Share this

Alnylam's Oxlumo (lumasiran) Receives the US FDA's Approval for Treatment of Primary Hyperoxaluria Type 1 in Pediatric and Adult Patients

Shots:

  • The approval is based on P-III ILLUMINATE-A & -B trials. The studies demonstrating reductions in urinary oxalate and encourage safety and tolerability in pediatric and adult patients
  • The ILLUMINATE-A showed that Oxlumo met its 1EP i.e. change in 24hrs. (65% vs 12%) compared to PBO- the study also achieved significant results for all 6 tested 2EPs
  • In ILLUMINATE-B- Oxlumo demonstrated a 72% mean reduction in spot urinary oxalate: creatinine ratio from baseline to 6mos.- reduction of oxalate as consistent across all three body wt. categories. Additionally- therapy demonstrated positive results across 2EPs- including additional measures of oxalate

 ­ Ref: Businesswire | Image: Bloomberg

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions